The role of ivermectin in the treatment of COVID-19 is still under debate, yet the drug has been widely used in some parts of the world, as shown by impressive market data. The available body of evidence may have changed over the last months, as studies have been retracted and âoestandards of careâ (SOC) used in control groups have changed with rapidly evolving knowledge on COVID-19. This review aims to summarize and critically appraise the evidence of randomized controlled trials (RCTs) of ivermectin, assessing clinical outcomes in COVID-19 patients.

. The evidence suggests that ivermectin does not reduce mortality risk and the risk of mechanical ventilation requirement. Although we did not observe an increase in the risk of adverse effects, the evidence is very uncertain regarding this endpoint.

First, the group of doctors championed ivermectin as a covid panacea. It failed to live up to the hype. Now, they're promoting the anti-parasitic to prevent and treat the flu and RSV. The Front Line Covid-19 Critical Care Alliance, formed in 2020 to "prevent and treat covid," is touting ivermectin for common respiratory infections amid a dramatic drop in prescriptions for the drug as clinical trials undermined claims of its efficacy against covid. There is no clinical data in humans to support using ivermectin for flu or RSV, according to the Centers for Disease Control and Prevention and other medical experts. And yet, the alliance publishes "treatment protocols" promoting the use of ivermectin for flu, RSV and covid that it says have been downloaded more than a million times. It also recommends a network of hundreds of medical providers and pharmacies that can provide prescriptions for ivermectin, often through virtual visits that can run hundreds of dollars.